Short- and long-term cost-effectiveness of CYP2C19 genotype-guided therapy, universal clopidogrel, and universal ticagrelor in post-percutaneous coronary intervention patients in Qatar

Patients having CYP2C19 loss-of-function alleles and receiving clopidogrel are at higher risk of adverse cardiovascular outcomes. Ticagrelor is an effective antiplatelet that is unaffected by the CYP2C19 polymorphism. The main aim of the current research is to evaluate the cost-effectiveness among CYP2C19 genotype-guided therapy, universal ticagrelor, and universal clopidogrel after a percutaneous coronary intervention (PCI).
Source: International Journal of Cardiology - Category: Cardiology Authors: Source Type: research